Evolent Health, Inc. Q1 FY2025 earnings call

• Organic growth: Five new revenue agreements across major condition areas, including new health plans for surgical management, expanded geographic reach of medical oncology solutions, and expansions in musculoskeletal and imaging services. Renewals with existing customers are strong, and the performance suite pipeline is the largest in history.
• Expanding profitability: On track with performance suite margin maturation and AI-led automation within the technology and services suite. Oncology trend leading indicators show moderation but not fully reflected in Q1 results.
• Capital allocation: Focus on balance sheet management, purchasing oncology navigation assets via a put-call structure, and no near-term M&A. Anticipate positive operating cash flow for the rest of 2025.
• Oncology: Launched oncology navigation solution combining internal protocols, purchased oncology care partners' assets, and integrated Careology's app. Piloting to cover 300,000 members by May with early success in integrations and patient navigation.
• Employee engagement: 2025 employee survey showed an 89% engagement rate, a strong score.

Evolent Health's first quarter revenue was $483.6 million. There were five new revenue agreements adding annualized specialty technology and services revenue of approximately $10 million and new lives on the platform of approximately 1 million. Contractual changes and true-ups impacted revenue, with one item contributing $55 million and another a retroactive minus $12.9 million with a net adjusted EBITDA impact of $400,000. The updated capitation rates for 2024 launches lowered 2025 revenue estimate by ~$33 million.

• Reiterated adjusted EBITDA outlook for 2025 between $135 million and $165 million.
• Revenue range for 2025 remains $2.06 billion to $2.11 billion.
• Q2 revenue guide $440 million to $470 million, with adjusted EBITDA $33 million to $40 million.
• Oncology trend guidance remains 12% for April-December despite Q1 being lower.

• Policy impacts: Potential Medicaid work requirements estimated to impact <5% of membership, $8M-$10M in adjusted EBITDA. Diversification across Medicaid, Medicare Advantage, and commercial lines insulates from policy swings.
• Tariffs: Performance suite contracts have clauses to update rates if unit costs change due to international trade dynamics.

Q: Kevin Caliendo asked about the sequential decline in Performance Suite PMPM due to lower MA revenue mix.

A: John Johnson said it's a baseline level, with a new MA oncology go-live later in the year expected to tick up.

Q: Matthew Gillmor inquired about oncology trend visibility.

A: John Johnson explained leading indicators (authorizations down vs forecasted up 12%) and claims completion (55%-60% complete at quarter close).

Q: Ryan Daniels asked about oncology product expansion.

A: Seth Blackley said it increases value/savings opportunity, helps with sales conversion and total savings dollars.

Q: Jessica Tassan asked about Performance Suite lives and repricing.

A: John Johnson talked about ~600,000 lives converting out of performance suite into tech and services, and annual recontracting cycle for repricing.

Q: Jeff Garro asked about Performance Suite gross margins and risk corridors.

A: John Johnson said no risk corridor positions yet, and consistent margins across payers at macro level.

Q: Kyle Aikman asked about oncology cost trend.

A: John Johnson said trend below 12% due to lower prevalence and cost per case, driven by clinical interventions.

Q: Matthew Shea asked about commercial demand.

A: Seth Blackley said strong demand across lines, using existing staff, and oncology is a top issue for self-funded employers.

Q: Constantine DeVis asked about AI automation.

A: Seth Blackley talked about efficiency improvements in provider/patient experience and auto authorization, with no denial of care.

Q: Charles Rhyee asked about oncology trend update.

A: John Johnson said Q2 needed for update, with leading indicators similar to Q1.

Q: Daniel Grosslight asked about competitive environment.

A: Seth Blackley said competitive environment unchanged, strong weighted pipeline.

Q: David Larsen asked about tariffs.

A: John Johnson said performance suite contracts have clauses to adjust rates in case of unit cost changes.